Compare SPCB & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | LSTA |
|---|---|---|
| Founded | 1988 | 1980 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 20.9M |
| IPO Year | N/A | N/A |
| Metric | SPCB | LSTA |
|---|---|---|
| Price | $8.90 | $2.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $18.00 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 92.5K | 23.8K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $26,739,000.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.13 | N/A |
| P/E Ratio | $11.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.14 | $1.81 |
| 52 Week High | $18.95 | $4.20 |
| Indicator | SPCB | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 47.29 |
| Support Level | $8.64 | $1.97 |
| Resistance Level | $9.92 | $2.15 |
| Average True Range (ATR) | 0.49 | 0.13 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 28.62 | 62.50 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.